New probody immuno-oncology study for solid tumors

October 30, 2019

Probody therapeutics are an emerging class of immuno-oncology therapies aimed at reducing the immune-related side effects associated with immune checkpoint inhibitors. A new multicohort study at the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center, tests the anticancer effects of an experimental probody therapeutic in patients with solid cancers:

CX-072 is a probody therapeutic directed against the programmed cell death ligand 1 (PD-L1) in the tumor microenvironment. By targeting the tumor microenvironment, CX-072 enhances the T-cell-mediated anticancer immune response while reducing immune-related side effects in healthy, peripheral tissues.

This phase II study will evaluate the clinical activity of CX-072 in combination with other anticancer therapies in four cohorts of adults with solid tumors:

  • Front-line therapy for patients with solid tumors who have received no prior therapy
  • Patients with progressive or relapsed solid tumors following PD-1/PD-L1 therapy
  • Patients with advanced/unresectable or metastatic disease following platinum-based therapy
  • Neoadjuvant therapy for patients with solid tumors who have received no prior therapy

A prior study of CX-072 monotherapy showed anticancer activity and a favorable safety profile in patients with advanced or unresectable solid tumors.

For more information or to enroll a patient, call our Clinical Research office at 503-215-2614 or submit a referral form.

See more studies

New research studies are added frequently. Please visit our website to view studies for all cancer types currently open at Providence Cancer Institute.